The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma

Chest

Volumn 111, Issue 1, 1997, Pages 106-109

  Renshaw, Andrew A ^a   Dean, Barbara R ^a   Antman, Karen H ^c   Sugarbaker, David J ^a,b   Cibas, Edmund S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c College of Physicians and Surgeons ^*  (United States)

Author keywords

asbestos; clinical presentation; cytogenetics; cytology; diagnosis; mesothelioma; pleural fluid

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; MALIGNANT MESOTHELIOMA; MEDICAL RECORD; PLEURA BIOPSY; PLEURA EFFUSION; PRIORITY JOURNAL; SURVIVAL;

EID: 0031038316     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.111.1.106     Document Type: Article

References (16)

1. Legha SS, Muggia FM. Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med 1977; 87:613-21
2. Sridhar KS, Doria R, Raub WA, et al. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992; 70:2969-79
3. Antman KH, Blum RH, Greenberger JS, et al. Mulitmodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980; 68:356-62
4. Elmes PC, Simpson MJC. The clinical aspects of mesothelioma. Q J Med 1976; 179:427-49
5. Oels HC, Harrison EG, Carr DT, et al. Diffuse malignant mesothelioma of the pleura: a review of 37 cases. Chest 1971; 60:564-70
6. Weissmann LB, Antman KH. Incidence, presentation, and promising new treatment for malignant mesothelioma. Oncology 1989; 3:67-72
7. Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma. Ann Intern Med 1982; 96:746-55
8. Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol 1981; 8:313-20
9. Ribak J, Lilis R, Suzuki Y, et al. Malignant mesothelioma in a cohort of asbestos workers: clinical presentation, diagnosis and cause of death. Br J Indust Med 1988; 45:182-87
10. Martini N, McCormack PM, Bains MS, et al. Pleural mesothelioma. Ann Thorac Surg 1987; 43:113-20
11. Sherman ME, Mark EJ. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma. Arch Pathol Lab Med 1990; 114:845-51
12. Granados R, Cibas ES, Fletcher JA. Cytogenetic analysis of effusions from malignant mesothelioma: a diagnostic adjunct to cytology. Acta Cytol 1994; 38:711-17
13. Fletcher JA. Cytogenetic aberrations in malignant soft tissue tumors. Adv Pathol Lab Med 1991; 4:235-46
14. Sugarbaker DJ, Heher EC, Lee TH, et al. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991; 102:10-4
15. Sugarbaker DJ, Strauss GM, Lynch TJ, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993; 11:1172-78
16. Sugarbaker DJ, Liptay MJ. Therapeutic approaches for malignant pleural mesothelioma. In: Aisner J, Arrigada R, Green MR, et al, eds. Comprehensive textbook of thoracic oncology. Baltimore: Williams & Wilkins; 1996, 786-98